PURPOSE: To evaluate myeloperoxidase (MPO) as a newer therapeutic target and bis-5-hydroxytryptamide-diethylenetriaminepentaacetate-gadolinium (Gd) (MPO-Gd) as an imaging biomarker for demyelinating diseases such as multiple sclerosis (MS) by using experimental autoimmune encephalomyelitis (EAE), a murine model of MS. MATERIALS AND METHODS: Animal experiments were approved by the institutional animal care committee. EAE was induced in SJL mice by using proteolipid protein (PLP), and mice were treated with either 4-aminobenzoic acid hydrazide (ABAH), 40 mg/kg injected intraperitoneally, an irreversible inhibitor of MPO, or saline as control, and followed up to day 40 after induction. In another group of SJL mice, induction was performed without PLP as shams. The mice were imaged by using MPO-Gd to track changes in MPO activity noninvasively. Imaging results were corroborated by enzymatic assays, flow cytometry, and histopathologic analyses. Significance was computed by using the t test or Mann-Whitney U test. RESULTS: There was a 2.5-fold increase in myeloid cell infiltration in the brain (P = .026), with a concomitant increase in brain MPO level (P = .0087). Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. MPO inhibition was accompanied by decreased demyelination (P = .01) and lower inflammatory cell recruitment in the brain (P < .0001), suggesting a central MPO role in inflammatory demyelination. Clinically, MPO inhibition significantly reduced the severity of clinical symptoms (P = .0001) and improved survival (P = .0051) in mice with EAE. CONCLUSION: MPO may be a key mediator of myeloid inflammation and tissue damage in EAE. Therefore, MPO could represent a promising therapeutic target, as well as an imaging biomarker, for demyelinating diseases and potentially for other diseases in which MPO is implicated.
PURPOSE: To evaluate myeloperoxidase (MPO) as a newer therapeutic target and bis-5-hydroxytryptamide-diethylenetriaminepentaacetate-gadolinium (Gd) (MPO-Gd) as an imaging biomarker for demyelinating diseases such as multiple sclerosis (MS) by using experimental autoimmune encephalomyelitis (EAE), a murine model of MS. MATERIALS AND METHODS: Animal experiments were approved by the institutional animal care committee. EAE was induced in SJL mice by using proteolipid protein (PLP), and mice were treated with either 4-aminobenzoic acid hydrazide (ABAH), 40 mg/kg injected intraperitoneally, an irreversible inhibitor of MPO, or saline as control, and followed up to day 40 after induction. In another group of SJL mice, induction was performed without PLP as shams. The mice were imaged by using MPO-Gd to track changes in MPO activity noninvasively. Imaging results were corroborated by enzymatic assays, flow cytometry, and histopathologic analyses. Significance was computed by using the t test or Mann-Whitney U test. RESULTS: There was a 2.5-fold increase in myeloid cell infiltration in the brain (P = .026), with a concomitant increase in brain MPO level (P = .0087). Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. MPO inhibition was accompanied by decreased demyelination (P = .01) and lower inflammatory cell recruitment in the brain (P < .0001), suggesting a central MPO role in inflammatory demyelination. Clinically, MPO inhibition significantly reduced the severity of clinical symptoms (P = .0001) and improved survival (P = .0051) in mice with EAE. CONCLUSION:MPO may be a key mediator of myeloid inflammation and tissue damage in EAE. Therefore, MPO could represent a promising therapeutic target, as well as an imaging biomarker, for demyelinating diseases and potentially for other diseases in which MPO is implicated.
Authors: Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman Journal: Nat Med Date: 2010-03-28 Impact factor: 53.440
Authors: Filip K Swirski; Moritz Wildgruber; Takuya Ueno; Jose-Luiz Figueiredo; Peter Panizzi; Yoshiko Iwamoto; Elizabeth Zhang; James R Stone; Elisenda Rodriguez; John W Chen; Mikael J Pittet; Ralph Weissleder; Matthias Nahrendorf Journal: J Clin Invest Date: 2010-06-23 Impact factor: 14.808
Authors: Anna Klinke; Claudia Nussbaum; Lukas Kubala; Kai Friedrichs; Tanja K Rudolph; Volker Rudolph; Hans-Joachim Paust; Christine Schröder; Daniel Benten; Denise Lau; Katalin Szocs; Paul G Furtmüller; Peter Heeringa; Karsten Sydow; Hans-Jürgen Duchstein; Heimo Ehmke; Udo Schumacher; Thomas Meinertz; Markus Sperandio; Stephan Baldus Journal: Blood Date: 2010-10-27 Impact factor: 22.113
Authors: John A Ronald; John W Chen; Yuanxin Chen; Amanda M Hamilton; Elisenda Rodriguez; Fred Reynolds; Robert A Hegele; Kem A Rogers; Manel Querol; Alexei Bogdanov; Ralph Weissleder; Brian K Rutt Journal: Circulation Date: 2009-08-03 Impact factor: 29.690
Authors: Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder Journal: Proc Natl Acad Sci U S A Date: 2008-11-14 Impact factor: 11.205
Authors: Matthias Nahrendorf; David Sosnovik; John W Chen; Peter Panizzi; Jose-Luiz Figueiredo; Elena Aikawa; Peter Libby; Filip K Swirski; Ralph Weissleder Journal: Circulation Date: 2008-02-11 Impact factor: 29.690
Authors: Yinian Zhang; Daniel P Seeburg; Benjamin Pulli; Gregory R Wojtkiewicz; Lionel Bure; Wendy Atkinson; Stefan Schob; Yoshiko Iwamoto; Muhammad Ali; Wei Zhang; Elisenda Rodriguez; Andrew Milewski; Edmund J Keliher; Cuihua Wang; Yawen Pan; Filip K Swirski; John W Chen Journal: Radiology Date: 2015-09-23 Impact factor: 11.105
Authors: Kevin Li-ChunHsieh; Stefan Schob; Matthias W G Zeller; Benjamin Pulli; Muhammad Ali; Cuihua Wang; Terry Ting-Yu Chiou; Yuk-Ming Tsang; Po-Shun Lee; Thomas P Stossel; John W Chen Journal: J Neuroimmunol Date: 2015-08-09 Impact factor: 3.478
Authors: Klara Kirschbaum; Jana K Sonner; Matthias W Zeller; Katrin Deumelandt; Julia Bode; Rakesh Sharma; Thomas Krüwel; Manuel Fischer; Angelika Hoffmann; Milene Costa da Silva; Martina U Muckenthaler; Wolfgang Wick; Björn Tews; John W Chen; Sabine Heiland; Martin Bendszus; Michael Platten; Michael O Breckwoldt Journal: Proc Natl Acad Sci U S A Date: 2016-10-31 Impact factor: 11.205
Authors: Benjamin Pulli; Lionel Bure; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Muhammad Ali; Dan Li; Stefan Schob; Kevin Li-Chun Hsieh; Andreas H Jacobs; John W Chen Journal: Radiology Date: 2014-12-10 Impact factor: 11.105
Authors: Hassan Albadawi; John W Chen; Rahmi Oklu; Yue Wu; Gregory Wojtkiewicz; Benjamin Pulli; John D Milner; Richard P Cambria; Michael T Watkins Journal: Radiology Date: 2016-08-10 Impact factor: 11.105